Univariate and multivariate Cox proportional hazards models for combined adverse outcomes including cardiac death, hospitalisation for heart failure, and life-threatening arrhythmias
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| Variable | Unadjusted HR (95% CI) | p Value | Adjusted HR(95%CI) | p Value |
| Age* | 1.07 (0.71 to 1.74) | 0.765 | – | – |
| Male | 1.75 (0.63 to 4.87) | 0.279 | – | – |
| NYHA functional class† | 2.45 (1.08 to 5.73) | 0.032 | 2.40 (1.04 to 5.80) | 0.040 |
| eGFR‡ | 1.00 (0.96 to 1.03) | 0.852 | – | – |
| BNP§ | 5.60 (1.19 to 30.9) | 0.028 | 0.71 (0.10 to 5.43) | 0.740 |
| CMR analysis | ||||
| LVEF¶ | 0.80 (0.62 to 1.00) | 0.049 | 0.89 (0.67 to 1.19) | 0.463 |
| LV end-diastolic volume index** | 1.08 (0.96 to 1.21) | 0.203 | – | – |
| LV end-systolic volume index** | 1.13 (0.99 to 1.26) | 0.065 | – | – |
| LV mass index†† | 1.00 (0.81 to 1.21) | 0.979 | – | – |
| % LGE mass¶ | 1.71 (1.26 to 2.47) | 0.001 | 1.64 (1.10 to 2.66) | 0.015 |
Multivariable model included NYHA functional class, BNP, LVEF and %LGE mass.
*HR reflects risk with an increase of 10 years.
†With an increase of 1 functional class.
‡With an increase of 1 mL/min/1.73 m2.
§With an increase of 1 logBNP.
¶With an increase of 5%.
**With an increase of 10 mL/m2.
††With an increase of 10 g/m2.
BNP, B-type natriuretic peptide; CMR, cardiovascular magnetic resonance; eGFR, estimated glomerular filtration rate; LGE, late gadolinium enhancement. NYHA, New York Heart Association.